araag2/HINT huggingface dataset:
Clinical trial NCT00346359 (phase 2, status: completed)
Conditions: chronic myeloproliferative disorders, graft versus host disease, leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases
ICD codes: D47.1, D89.810, D89.811, D89.813, D89.812, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: busulfan, fludarabine phosphate, methotrexate, tacrolimus
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following myeloid malignancies:

               -  Chronic myelogenous leukemia meeting 1 of the following criteria:

                    -  Chronic phase

                    -  Accelerated phase

                    -  Treated blast phase

               -  Acute myeloid leukemia meeting 1 of the following criteria:

                    -  In remission

                    -  In early relapse, defined as < 10% marrow blasts

               -  Myelodysplastic syndromes, including all risk groups

               -  Other myeloproliferative disorders

          -  HLA-A, -B, -C, -DRB1, and -DQB1 matched related or unrelated donor available

        PATIENT CHARACTERISTICS:

          -  No other disease that would severely limit life expectancy

          -  AST ≤ 2 times normal

          -  Creatinine ≤ 2 times normal OR creatinine clearance ≥ 60 mL/min

          -  No cardiac insufficiency requiring treatment

          -  No symptomatic coronary artery disease

          -  PO_2 ≥ 70 mm Hg AND DLCO ≥ 70% of predicted OR PO _2 ≥ 80 mm Hg AND DLCO ≥ 60% of
             predicted

          -  HIV negative

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No post-transplantation growth factor during methotrexate administration
Clinical trial NCT00664326 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: regorafenib (stivarga, bay73-4506)
SMILES: O=[Zn]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients >/= 18 years of age.

          -  Patients, who suffer from unresectable and/or metastatic, measurable predominantly
             clear cell RCC (renal cell carcinoma histologically) or cytologically documented.

          -  Patients must be previously untreated for advanced disease. Prior palliative radiation
             therapy is allowed if the target lesion(s) are not included within the radiation field
             and no more than 30% of the bone marrow is irradiated.

          -  Patients who have at least one uni-dimensional measurable lesion by computed
             tomography (CT-scan) or magnetic resonance imaging (MRI) according to Response
             Evaluation Criteria in Solid Tumors (RECIST).

          -  Patients with "Intermediate" or "Low" risk per the Motzer score.

          -  Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of
             0 or 1.

          -  Adequate bone marrow, renal and hepatic function as assessed by the following
             laboratory requirements to be conducted within 7 days prior to study drug treatment

        Exclusion Criteria:

          -  Patients who have received prior systemic treatment regimens for RCC.

          -  Uncontrolled/unstable cardiac disease

          -  Uncontrolled hypertension

          -  Active clinically serious infections (> Common Terminology Criteria for Adverse Events
             [CTCAE] grade 2 )

          -  History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.

          -  Known history or symptomatic metastatic brain or meningeal tumours

          -  Patients with seizure disorder requiring medication

          -  Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding
             event >/= CTCAE Grade 3 within 4 weeks of first dose of study.

          -  Pregnant or breast-feeding patients
Clinical trial NCT00062010 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: 13-cis-retinoic acid, paclitaxel
SMILES: C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria

          -  Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) with
             clinically confirmed measurable disease

          -  Age 18 and over

          -  ECOG Performance status 0-3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST no greater than 2 times upper limit of normal (ULN)

          -  Creatinine no greater than 1.5 mg/dL

          -  Triglycerides no greater than 1.5 times ULN

          -  Patients must have had prior chemotherapy treatment for SCLC, and toxicities must have
             resolved to less than or equal to grade 1

          -  Women of childbearing potential and sexually active males are strongly encouraged to
             use an accepted and effective method of contraception.

        Exclusion Criteria

          -  History of another neoplasm other than SCLC except for non-metastatic, non-melanoma
             skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small
             field radiotherapy at least 5 years before registration

          -  Pregnant or nursing, with a negative pregnancy test within 2 weeks prior to
             registration

          -  Severe depression requiring medication

          -  Use of the following drugs within 4 weeks prior to registration: carbamazepine,
             ethanol, tetracycline, doxycycline, minocycline, topical acne products containing
             Retin-A, vitamin A, cisplatin, ketoconazole, phenytoin or other antiepileptic drugs

          -  Use of GM-CSF or G-CSF within 4 weeks prior to registration

          -  Prior paclitaxel or interferon therapy

          -  Radiation therapy within 60 days prior to registration

          -  Chemotherapy within 60 days prior to registration
Clinical trial NCT00704405 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: vaniprevir, pegylated interferon (peg-ifn), ribavirin (rbv), placebo (pbo)
SMILES: [H][C@@]1(CC)C[C@]1(N=C(O)[C@]1([H])C[C@]2([H])CN1C(=O)[C@@]([H])(N=C(O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(O)=NS(=O)(=O)C1CC1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Has chronic HCV genotype 1 infection

          -  Is treatment-experienced

          -  For the non-cirrhotic population, has had a liver biopsy without evidence of cirrhosis
             and hepatocellular carcinoma; for the cirrhotic population, has had a liver biopsy
             with evidence of cirrhosis and without evidence of hepatocellular carcinoma.

        Exclusion criteria:

          -  Has not tolerated previous course peg-IFN and RBV

          -  Is unlikely to tolerate at least 24 weeks of continuous therapy with Peg-IFN and RBV

          -  Is co-infected with Human Immunodeficiency Virus (HIV) and/or hepatitis B

          -  Consumes excessive amounts of alcohol

          -  Has a history of drug or alcohol abuse

          -  If female, participant is pregnant or breastfeeding

          -  Has been in a clinical trail with an investigational drug in the last 30 days

          -  Has used IFN/Peg-IFN and RBV in the last 3 months
Clinical trial NCT00460941 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, taspoglutide 20mg, taspoglutide 20mg-30mg, taspoglutide 20mg-40mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  male,and post-menopausal or surgically sterilized female, patients, 18-75 years of
             age;

          -  type 2 diabetes mellitus, with stable metformin treatment for >=3 months;

          -  HbA1c >=7.0% and <=9.5% at screening;

          -  stable weight +/-10% for >=3 months before screening.

        Exclusion Criteria:

          -  type 1 diabetes mellitus;

          -  clinically significant gastrointestinal disease;

          -  treatment with any anti-hyperglycemic medication other than metformin monotherapy
             during last 3 months;

          -  use of weight-lowering medications in the last 3 months;

          -  uncontrolled hypertension;

          -  previous exposure to GLP-1 or GLP-1 analogues.
Clinical trial NCT00086346 (phase 3, status: terminated)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: sirolimus (rapamune), cyclosporine or tacrolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Age greater than 13 years (age greater than 18 years as required by some local
             regulations).

          -  Receiving immunosuppressive therapy with calcineurin inhibitors (CI) +/-
             corticosteroids +/- antimetabolite.

          -  6 to 144 months after orthotopic liver transplantation.

          -  Cockcroft-Gault GFR values ≥40 mL/min and ≤90mL/min at screening

        Exclusion Criteria:

          -  History of nonhepatic transplantation

          -  Evidence of systemic infection (sepsis, bacteremia, pneumonia etc).

          -  Known or suspected malignancy < 5 years before random assignment.
Clinical trial NCT00428389 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rivastigmine 5 cm^2 transdermal patch, rivastigmine 10 cm^2 transdermal patch
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 50 years of age;

          -  Have a diagnosis of probable Alzheimer's Disease;

          -  Have an MMSE score of > or = 10 and < or = 24;

          -  Must have a caregiver who is able to attend all study visits;

          -  Have received continuous treatment with donepezil for at least 6 months prior to
             screening, and received a stable dose of 5 mg/day or 10 mg/day for at least the last 3
             of these 6 months.

        Exclusion Criteria:

          -  Have an advanced, severe, progressive, or unstable disease of any type that may
             interfere with efficacy and safety assessments or put the patient at special risk;

          -  Have a history of malignancy of any organ system, treated or untreated, within the
             past 5 years;

          -  Have a history within the past year or current diagnosis of cerebrovascular disease;

          -  Have a current diagnosis of severe or unstable cardiovascular disease; Have a history
             of myocardial infarction (MI) in the last six months;

          -  Severe or unstable respiratory conditions (e.g., severe asthma , severe pulmonary
             (lung) disease);

          -  Digestive problems related to peptic ulcer;

          -  Urinary obstruction or current severe urinary tract infection;

          -  Abnormal thyroid function tests;

          -  Low folate or Vitamin B12;

          -  Have a disability that may prevent the patient from completing all study requirements;

          -  Have a current diagnosis of an active skin lesion/disorder that would prevent adhesion
             of a patch;

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00280566 (phase 3, status: completed)
Conditions: bipolar mania, bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: placebo, ziprasidone oral capsule
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Eligibility criteria:

        Inclusion Criteria:

        Adults meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth
        Edition) criteria for Bipolar I Disorder (currently with manic or mixed symptoms)

        Exclusion Criteria:

        Ultra rapid cyclers and subjects with significant cardiovascular disease including history
        of QT prolongation and/or congenital long QT syndrome
Clinical trial NCT00696631 (phase 3, status: terminated)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: dronedarone (sr33589), placebo
SMILES: CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated as the active treatment was associated with an increased hazard
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients hospitalized with symptomatic CHF, current New York Heart Association (NYHA)
             class II-IV requiring treatment with a diuretic, who had had within the last month at
             least 1 episode of dyspnea or fatigue at rest, or on slight exertion corresponding to
             NYHA class III or IV

          -  Wall motion index (WMI) ≤1.2 determined by a blinded central evaluation of a recorded
             standard echocardiography, equivalent to a left ventricular ejection fraction (LVEF)
             ≤35%.

        Exclusion Criteria:

          -  acute pulmonary edema within 12 hours prior to start of study medication

          -  various heart conditions (cardiogenic shock, obstructive valvular disease, obstructive
             cardiomyopathy; acute myocardial infarction, cardiac surgery, acute myocarditis or
             constrictive pericarditis, history of torsades de pointes, bradycardia <50 bpm and/or
             PR-interval ≥280 ms, QTc-interval >500 ms, significant sinus node disease)

          -  any illness or disorder other than CHF (cancer with metastasis, organ transplantation)

          -  current participation in another clinical study or currently taking an investigational
             drug including dronedarone or concomitant prohibited medication or treatment with
             other class I or III anti-arrhythmic drugs

          -  pregnant and/or breastfeeding women or women of child-bearing potential without
             adequate birth control

          -  serum potassium <3.5 mmol/L.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00317642 (phase 3, status: completed)
Conditions: acute myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: clofarabine (iv formulation), placebo, cytarabine
SMILES: [H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of Acute Myelogenous Leukemia (AML) according to World Health
             Organization (WHO) classification

          -  Relapsed after receiving up to 2 prior induction regimens (i.e. first or second
             relapse)or are refractory to not more than one prior combination chemotherapy
             induction regimen

          -  Be ≥ 55 years of age

          -  Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2

          -  Be able to comply with study procedures and follow-up examinations

          -  Be nonfertile or agree to use birth control during the study through the end of
             treatment visit and for at least 90 days after the last dose of study drug

          -  Have adequate liver and renal function as indicated by certain laboratory values

        Exclusion Criteria:

          -  Received previous treatment with clofarabine

          -  Received bolus, intermediate or high-dose cytarabine as induction therapy unless
             certain remission criteria are met

          -  Have received a hematopoietic stem cell transplant (HSCT) within the previous 3 months

          -  Have moderate or severe graft versus host disease (GVHD), whether acute or chronic

          -  Are receiving any other chemotherapy or investigational therapy. Patients must have
             been off prior AML therapy for at least 2-6 weeks prior to entering study.

          -  Have a psychiatric disorder that would interfere with consent, study participation, or
             follow-up

          -  Have an active, uncontrolled infection

          -  Have any other severe concurrent disease, or have a history of serious organ
             dysfunction or disease involving the heart, kidney, liver, or other organ system

          -  Have been diagnosed with another malignancy, unless disease-free for at least 5 years;
             patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical
             intraepithelial neoplasia, regardless of the disease-free duration, are eligible for
             this study if definitive treatment for the condition has been completed; patients with
             organ-confined prostate cancer with no evidence of recurrent or progressive disease
             are eligible if hormonal therapy has been initiated or the malignancy has been
             surgically removed.

          -  Have clinical evidence suggestive of central nervous system (CNS) involvement with
             leukemia unless lumbar puncture confirms absence of leukemic blasts in the
             cerebrospinal fluid(CSF)

          -  Known HIV positivity

          -  Are pregnant or lactating
Clinical trial NCT00133224 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: chemotherapy (docetaxel and prednisone)
SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Reason stopped: 
    accrual and treatment with cg1940/cg8711 stopped due to idmc recommendation.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the
             prostate

          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy

          -  Detectable metastases

          -  ECOG performance status ≤2 (Performance status of 3 if due to bone pain)

          -  Any Gleason score

          -  Only one prior treatment with systemic chemotherapy

          -  No prior treatment with gene therapy

          -  No prior immunotherapy for prostate cancer

          -  Taxane naïve

          -  Experiencing cancer-related pain
Clinical trial NCT02728622 (phase 3, status: completed)
Conditions: ovarian cancer, peritoneal cancer, cancer of the fallopian tube
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: tamoxifen, chemotherapy
SMILES: OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with invasive epithelial ovarian, fallopian tube or peritoneal cancer, being
             resistant to treatment with platinum and a taxane, either given in combination or
             sequentially.

          -  Patients with clinical progression during or within 6 months after end of treatment
             for primary disease or relapse.

          -  Patients with stable disease after 6 courses of chemotherapy for primary disease or
             relapse if further treatment is indicated.

          -  Patients with doubling of s-CA 125 to at least 70 IU/Ml within 3 months after end of
             treatment for primary disease or relapse.

          -  Age must be at least 18 years.

          -  Performance status must be 0-2 (WHO/ECOG, appendix 1).

          -  Informed consent given according to ICH/EU GCP guidelines and local or national laws

        Exclusion Criteria:

          -  Patients with symptomatic brain metastasis

          -  Bilirubin greater than 2 x UNL (upper normal limits), white blood cell count below 3.0
             x 109/L, neutrophil count below 1.5 x 109/L, platelets count below 100 x 109/L.

          -  Active infection or other serious underlying medical condition which might prevent the
             patient from receiving treatment or to be followed.

          -  Pregnant, lactating, or child bearing potential patients without adequate
             contraception

          -  Previous treatment with Tamoxifen.